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The translocations that result in the formation of the PAX3/PAX7-FOXO1 fusion genes are strongly associated with alveolar rhabdomyosarcoma (ARMS) and are considered to be key drivers of this mainly youngonset sarcoma. The PAX3-FOXO1 fusion protein drives a major transcriptional programme and cohesive expression signature in these tumours [1] . This and previous functional work show cell death and differentiation results from ablation of the fusion protein in tumour-derived cells and have led to the view that the fusion protein is an Achilles heel of ARMS. The work carried out by Pandey et al [2] is the first to test the reliance of these tumours on the fusion gene in vivo beyond the stage of tumour initiation. They mimicked a targeting strategy by reducing levels of the fusion protein in an established tumour model and discovered that despite a dramatic initial response, tumours recurred that in some cases lacked PAX3-FOXO1 expression. This suggests that fusion-positive alveolar rhabdomyosarcomas may ultimately be capable of becoming independent of their defining genetic lesion.
Pandey et al used a model of ARMS in which inducible PAX3-FOXO1 is modulated in immortalized human myoblasts plus and minus constitutively active MYCN expression. Expression of either alone was not transformative in a focus formation assay, whereas transformation occurred with both PAX3-FOXO1 and MYCN. Injection of these modified myoblasts into mice resulted in rapid RMS tumour formation but with PAX3-FOXO1 expression alone, tumours only emerged after a long latency time. Switching off PAX3-FOXO1 in the PAX3-FOXO1/MYCN model resulted in tumour regression with cellular differentiation and apoptosis. However, subsequent recurrences frequently occurred, a minority of which were identified as PAX3-FOXO1-independent ( Figure 1 ).
Previous genetically engineered mouse models of ARMS include conditional expression of Pax3-Foxo1 in the myogenic lineage in a Myf6-dependent manner, [2] have shown that tumours and in vitro transformed clones arise when MYCN is constitutively expressed and PAX3-FOXO1 is induced in immortalized human myoblasts in an orthotopic xenograft model (in vivo). These regress when PAX3-FOXO1 expression is switched off; however, they recur in two ways: firstly, when cells re-express the fusion gene (PAX3-FOXO1-dependent); and, secondly, via a PAX3-FOXO1-independent mechanism. When tumour-derived cells from recurrences were transfected with PAX3-specific CRISPR constructs (ablating PAX3-FOXO1 transcription), colonies formed in tumourigenicity assays only if they were PAX3-FOXO1-independent. This confirms the lack of dependency on the fusion gene in these cells.
with cooperating Trp53 or Ink4a/ARF loss of function. A subcutaneous xenograft model of ARMS using transformed human myoblasts expressing PAX3-FOXO1 with silencing of INK4A/ARF has also been shown to form tumours resembling ARMS when MYCN and hTERT were concomitantly overexpressed (all reviewed in [3] ). The order in which these genes were expressed was found to be critical and, consistent with the current paper, tumours formed only when PAX3-FOXO1 was expressed early. Other models may ultimately prove informative, exemplified by a recent Pax3-Foxo1 mouse model generated by CRISPR technology, although tumours did not result with Pax3-Foxo1 alone [4] . However, the precise cooperating events and cell type that gives rise to ARMS in patients remain elusive.
Fusion gene addiction: can tumours be forced to give up the habit? 265 particular time points in the differentiation pathway, suggesting a role at certain stages of myogenic differentiation. Cells at these time points shared gene expression patterns with a fusion-positive ARMS cell line [6] . This suggests a non-oncogenic role of the fusion protein and underlines the importance of cellular context and cooperating events. Interestingly, the PAX3-FOXO1 fusion is also found in biphenotypic sinonasal sarcoma [7] , a low-grade sarcoma that has never been known to form distant metastases, yet does show both neural and myogenic features. It may be informative to see whether MYCN is expressed in these tumours along with fusion gene targets found in ARMS. Non-oncogenic fusion genes are also documented and the t(14;18)(q32;q21) and resultant fusion of IGH-BCL2, which is associated with follicular lymphoma, can be found in a quarter of healthy human adults [8] .
Whether loss of gene fusions occurs in tumours that persist is not clearly documented and an apparent recurrence without the original fusion would likely be interpreted as a second primary. Spontaneous loss of PAX3-FOXO1 is not documented in ARMS samples from patients, suggesting that tumours retain dependence on the fusion gene at all stages of disease. However, it is rare to confirm fusion gene expression in metastatic lesions in cases where a primary diagnosis of fusion gene-positive ARMS has been made. Presence of the fusion gene correlates with a significantly worse outcome than fusion-negative RMS and is now being used to stratify risk in patient management. This association with poor prognosis can be seen in those metastatic at diagnosis, suggesting that the fusion protein adversely alters tumour behaviour even at a late stage [9] .
The experiments reported by Pandey et al go beyond the previous models associated with transformation and tumour development by showing that tumours can reoccur that lack PAX3-FOXO1. However, interpretation of their results is necessarily nuanced by the nature and limitations of the model used. Their orthotopic xenograft model uses human myoblasts from a Duchenne muscular dystrophy patient associated with a dystrophin mutation, which have been immortalized by constitutive expression of hTERT and BMI-1, the latter disrupting the Rb and p53 pathways. Dystrophin is described with a tumour suppressor role in human cancers with myogenic programmes including RMS. The dystrophin-deficient muscular dystrophy model mdx mouse can spontaneously develop muscle tumours resembling either embryonal or alveolar RMS, albeit after a long latency [10] . It is not clear in this model whether lack of dystrophin is capable of playing a tumourigenic role. Additionally, the use of an inducible system needed to modulate temporal expression of PAX3-FOXO1 is inevitably associated with some level of leakiness in the system that prohibits us from concluding that the fusion gene is absolutely not required for tumour recurrence in this model. CRISPR Cas9 knockout of PAX3-FOXO1 adds reassurance in vitro but these experiments were not extended to reintroduction in in vivo tumourigenic assays.
The phenomenon of oncogene addiction has been well documented in the last decade where tumour cells appear highly dependent on a single oncogenic event, which when targeted, shows extreme initial vulnerability. The emergence of tumour cells that can overcome this addiction is still a major challenge for many targeted therapeutic approaches. Investigation of mechanisms of resistance to targeted treatments has largely focused on kinase inhibitors and almost always involves reactivation of the key oncogene, mutation (and subsequent activation) of downstream components, or use of an alternative downstream pathway. The mechanisms investigated remain intrinsically linked to the specific onocogene-activated pathways. It is noteworthy that a proportion of recurrent tumours in the current study re-expressed PAX3-FOXO1 when doxycycline was withdrawn, in an analogous manner to reinstating activation of the primary oncogene in kinase-addicted cells. Indeed, high expression of the fusion gene appears to be selected for in metastatic versus primary tumours in another mouse model of ARMS [11] , indicating a potential role in tumour progression.
It is now becoming a realistic possibility for therapeutics to indirectly reduce PAX3-FOXO1 levels [12] or even directly inhibit gene/fusion gene expression [13, 14] . Therefore, it is both pertinent and of considerable interest to interrogate the mechanisms of resistance that arise from loss of a transcription factor. The recurrence model used in this study is well suited to shed light on this previously unexplored aspect of RMS tumour biology. Unlike kinases, which have a more limited set of downstream pathways, transcription factors can have a multitude of downstream targets. Profiling and comparing the fusion gene-dependent and -independent recurrences that arose using this model will determine which, if any, of the targets retain a key role in the PAX3-FOXO1-independent tumour recurrences and reveal any shared mechanism. This may help to focus therapeutic efforts on signalling pathways common to both in an effort to circumvent anticipated resistance. The authors note that PAX3-FOXO1-independent recurrent tumour-derived cells achieve a differentiation block similar to fusion gene-dependent cells. Elucidating the mechanism for this may relate to tumour progression and have therapeutic implications. The model teaches us that ARMS may be able to become independent of the fusion gene but perhaps only when under severe selective pressure.
